No Data
No Data
Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy
Insmed Is Maintained at Overweight by JP Morgan
Demystifying Insmed: Insights From 7 Analyst Reviews
Insmed Analyst Ratings
J.P. Morgan Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $83
Optimistic Revenue Forecast for Insmed Following Brensocatib's Launch and Strategic Developments